Skip to main content

MoneyWorks4Me

Lupin informs about disclosure

05 Oct 2024 Evaluate
Lupin has informed that the US FDA has completed a Pre-Approval Inspection of Biotech facility located in Pune, India. The inspection was carried out from September 25, 2024 to October 4, 2024, and concluded with five observations. The Company is addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe. This is considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1880.90
Dr. Reddys Labs. 1377.00
Cipla 1393.00
Lupin 1980.00
Zydus Lifesciences 1191.00
View more..